MedTrace Logo

Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma

NCT00928668 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-07-01

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to assess the efficacy (bronchoprotection) and safety of single doses of BI 1744 CL inhalation solution (2, 5, 10 and 20 mcg) delivered via the Respimat® inhaler, in patients with intermittent asthma.

Conditions

Interventions

DRUG

Placebo

Placebo device for comparison

DRUG

Olodaterol (BI1744CL)

Olodaterol comparison of low, medium low, medium high and high doses

DRUG

Olodaterol (BI1744CL)

Olodaterol comparison of low, medium low, medium high and high doses

DRUG

Olodaterol (BI1744CL)

Olodaterol comparison of low, medium low, medium high and high doses

DRUG

Olodaterol (BI1744CL)

Olodaterol comparison of low, medium low, medium high and high doses

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2006-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00928668 on ClinicalTrials.gov